Recorded Presentation from the NCCN Pharmacy Updates: The Role of PD-L1 Therapy in the Early Treatment of Triple Negative Breast Cancer
Triple-negative breast cancer continues to be labeled with a poor prognosis secondary to the fact that it tends to be more aggressive and poses a greater risk of recurrence. Because it lacks the receptors that many drugs have been designed to target, the standard of practice remains chemotherapy. Therefore, research has been focused on trying to identify other therapeutic targets for which agents already exist or are currently being developed. Within recent years, PD-L1 inhibition is being studied in trials as a new avenue for treatment options in these patients. Current evidence demonstrates increased benefit when using these agents in combination with chemotherapy.
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Clinical Scenario #2: Applying Biomarkers in Breast Cancer
To provide optimal patient care, clinicians need to be well informed about the factors affecting the selection of the appropriate tests, the nuances of analyzing and interpreting complex test results in order to select the most appropriate treatment for their patients, and how to communicate with patients about the results.
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Recognizing Bias and Health Care Disparities in Black Patients
The goal of this initiative is to increase awareness, knowledge, and competence in the need for culturally sensitive, evidence-based, guideline recommended approaches for the treatment of breast and prostate cancer in Black patients.
Category
  • Breast Cancer
  • Disparities
  • Prostate Cancer
Format
  • Enduring Activity
Credits
  • 0.25 AAPA Category 1 CME credit
  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 ANCC contact hours
  • 0.25 Participation
Diagnosis and Management of Breast Cancer: What does the Evidence Show, What are We Doing, And What’s on the Horizon?
The goal of this initiative is to increase awareness, knowledge, and competence in the need for culturally sensitive, evidence-based, guideline recommended approaches for the treatment of breast cancer in Black patients.
Category
  • Breast Cancer
  • Disparities
Format
  • Enduring Activity
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Comorbidities, Dosing Issues, Polypharmacy, and Adverse Effects in Breast Cancer
The goal of this initiative is to increase awareness, knowledge, and competence in the need for culturally sensitive, evidence-based, guideline recommended approaches for the treatment of breast cancer in Black patients.
Category
  • Breast Cancer
  • Disparities
Format
  • Enduring Activity
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Disparities in Breast Cancer Screening and Management
Clinicians need to recognize that these disparities exist and the causes for the disparities to optimally manage their patients with breast cancer.
Category
  • Breast Cancer
  • Disparities
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation

Pages